1.Young, IR, Hall, AS, Pallis, CA, et al. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981; 2: 1063–1066.
2.Lukes, SA, Crooks, LE, Aminoff, MJ, et al. Nuclear magnetic resonance imaging in multiple sclerosis. Ann Neurol 1983; 13: 592–601.
3.Gonzales-Scarano, F, Grossman, RI, Galletta, S, Atlas, SW, Silberberg, DH.Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann Neurol 1987; 21:300–306.
4.Grossman, RI, Braffman, BH, Brorson, JR, et al. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 1988; 169: 117–122.
5.Isaac, C, Li, DKB, Genton, M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988; 38: 1511–1515.
6.Miller, DH, Rudge, P, Johnson, G, et al. Serial gadolinium-enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111:927–939.
7.Willoughby, EW, Grochowski, E, Li, DKB, et al. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989; 25: 43–49.
8.Bastianello, S, Pozzilli, C, Bernardi, S, et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 1990; 40:591–595.
9.Kermode, AG, Tofts, PS, Thompson, AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990; 40: 229–235.
10.Harris, JO, Frank, JA, Patronas, N, McFarlin, DE, McFarlan, HF.Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29:548–555.
11.McFarland, HF, Frank, JA, Albert, PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758–766.
12.Kappos, L, Stadt, D, Ratzka, M, et al. Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis. Neuroradiology 1988; 30: 299–302.
13.Miller, DH, Barkhof, F, Berry, I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerned action guidelines. J Neurol Neurosurg Psychiatry 1991; 54: 683–688.
14.Miller, DH, Thompson, AJ, Morrissey, SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55: 450–453.
15.Fidler, JM, Quinn De Joj, S, Smith III, FR, Gibbons, JJ.Selective immunomodulation by the antineoplastic agent mitoxantrone. Non-specific adherent suppressor cell derived from mitoxantrone treated mice. J Immunol 1986; 136: 2747–2754.
16.Fidler, JM, Quinn De Joj, S, Gibbons, JJ.Selective immunomodulation by the antineoplastic agent mitoxantrone. Suppression of B lymphocyte function. J Immunol 1986; 137: 727–732.
17.Levine, S, Saltzam, A.Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol 1986; 13: 175–181.
18.Gonsette, RE, Demonty, L.Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 1990; 40 (Suppl 1): 261.
19.Kappos, L, Gold, R, Kunstler, E, et al. Mitoxantrone (MX) in the treatment of rapidly progressive multiple sclerosis: a pilot study with serial gadolinium (GD)-enhanced MRI. Neurology 1990; 40 (Suppl 1): 261.
20.Noseworthy, JH, Lee, D, Penman, M, et al. A phase II evaluation of mitoxantrone HC1 in the treatment of progressive multiple sclerosis. Neurology 1991; 41 (Suppl 1): 146.
21.Noseworthy, JH, Hopkins, MB, Vandervoort, MK, et al. An opentrial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993; 43: 1401–1406.
22.Paty, D, Willoughby, E, Whithaker, J.Assessing the outcome of experimental therapies in multiple sclerosis patients. In: “Treatment of Multiple Sclerosis. Trial Design, Results and Future Perspectives.” Rudick, RA, Goodkìn, DE, eds. Springer-Verlag, Germany 1992: 47–90.
23Poser, CM, Paty, DW, Scheinberg, L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227–231.
24.Kurtzke, JF.Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1442–1452.
25.Goodkin, DE, Ross, JS, Vanderbrug Medendorp, S, Konecsni, J, Rudick, RA.Magnetic resonance imaging lesion enlargement in multiple sclerosis. Disease-related activity, chance occurrence, or measurement artefact? Arch Neurol 1992; 49: 261–263.
26.McDonald, WI.The dynamics of multiple sclerosis. J Neurol 1993; 240: 28–36.
27.Kurtzke, JF.Neuroepidemiology. Part II: assessment of therapeutic trials. Ann Neurol 1986; 19: 311–319.
28.Weinshenker, BG, Rice, GPA, Noseworthy, JH, et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991; 114: 1057–1067.
29.Matthews, WB, Matthews, WC, eds. McAlpine’s Multiple Sclerosis, 2nd ed. Edinburgh, Churchill Livingstone, 1991.
30.Thompson, AJ, Kermode, AG, Wicks, D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29: 53–62.